Rapid Pancreatic and Ovarian Screening MR Imaging With Motion Corrected T1, T2, and Advanced Diffusion Weighted Imaging for Patients With BRCA Mutation Who Undergo Screening Breast MRI

Pilot Study Pancreatic and Ovarian Screening MR Imaging of Rapid With Motion Corrected T1, T2, and Advanced Diffusion Weighted Imaging for Patients With BRCA Mutation Who Undergo Screening Breast MRI

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02462460

Enrollment

Registered

2015-06-04

Start date

2015-06-01

Completion date

2027-06-01

Last updated

2026-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Screening Breast MRI in Patients Who Are BRCA Mutation Carriers

Keywords

Breast MRI, T1 weighted and diffusion weighted MR, screening pancreatic, screening ovarian, 15-120

Brief summary

The purpose of this study is to create a rapid scan of the pancreas and ovaries that could be used in the future to screen patients at risk for pancreatic or ovarian cancers. Currently, Magnetic Resonance Imaging (MRI) examinations of the pancreas and ovaries can last 30-45 minutes each. The investigators hope to create a rapid pancreatic and ovarian MRI evaluation that can be used as a screening tool that is completed in approximately 15 minutes. They will compare different tools available on modern MRI scanners to see which one reliably offers high quality images of the pancreas and ovaries.

Interventions

DEVICEMRI

BEHAVIORALOptional Screening Questionnaire

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

30 Years to No maximum

Healthy volunteers

Inclusion criteria

A minimum of 5 and maximum of 60 evaluable patients will be imaged on this study. Description of the subject inclusion and

Exclusion criteria

are listed below. Inclusion Criteria: * BRCA 1 or 2 mutation * Age ≥ 30 * Patients scheduled to undergo screening breast MRI with contrast

Design outcomes

Primary

Measure	Time frame	Description
define optimized acquisition	1 year	The images will be evaluated qualitatively for image quality from 1 to 5 with 5 = not adequate and 1 = adequate image quality by two radiologists in consensus. If both radiologists give a score of 1, the sequence will be considered to be adequate in image quality. Quantitative measurements of SNR will be performed on the pancreatic head, body and tail, and ovarian tissue by region of interest (ROI) analysis. Final acquisition times and spatial resolution for each sequence will be recorded.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORPeter Sawan, MD

Memorial Sloan Kettering Cancer Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 3, 2026